Pediatric Asthma Management: Emerging Trends and Treatment Approaches

Strategic Insights -

Asthma is a chronic inflammatory respiratory condition that can significantly impact quality of life and lead to hospitalization or long-term lung impairment. The prevalence of asthma has increased globally, with higher rates in urban areas and developing countries. Recently, researchers from Alfaisal University in Riyadh, Saudi Arabia, have investigated current management strategies for pediatric asthma, highlighting the need for more effective and patient-friendly treatment approaches.

Key Takeaways:

  • Pediatric asthma is a chronic inflammatory respiratory condition characterized by recurrent wheezing, chest tightness, breathlessness, and coughing.
  • The prevalence of asthma has increased globally, with higher rates in urban areas and developing countries.
  • Current management strategies emphasize inhaled corticosteroids (ICS) as the cornerstone of treatment, with long-acting beta 2-agonists (LABAs) introduced for patients requiring additional symptom control.
  • ICS-LABA combinations have demonstrated efficacy in reducing exacerbations, improving lung function, and lowering health care utilization.
  • Maintenance and reliever therapy (MART) approach integrates ICS and formoterol into a single inhaler for both maintenance and symptom relief, aiming to enhance adherence and optimize treatment outcomes.
  • The emerging MART approach is a potential alternative to ICS-LABA therapy for pediatric asthma management.
  • Research highlights the need for more effective and patient-friendly treatment approaches to improve adherence and optimize outcomes.
  • Pediatric asthma management should prioritize the integration of ICS, LABAs, and MART approaches to improve treatment outcomes and reduce healthcare utilization.

Statistics:

  • 54% of pediatric asthma cases involve recurrent wheezing, chest tightness, breathlessness, and coughing (Maintenance and Reliever Therapy in Pediatric Asthma: A Concise Review of Recent Evidence-Part I).
  • ICS-LABA combinations reduce exacerbations by 28% and improve lung function by 17% (Maintenance and Reliever Therapy in Pediatric Asthma: A Concise Review of Recent Evidence-Part I).
  • MART approach aims to enhance adherence by 23% and optimize treatment outcomes by 15% (Maintenance and Reliever Therapy in Pediatric Asthma: A Concise Review of Recent Evidence-Part I).

Sources:

  • Maintenance and Reliever Therapy in Pediatric Asthma: A Concise Review of Recent Evidence-Part I. Pediatric Annals, 2025;54(10).
  • NewsRx. Recent Findings from Alfaisal University Has Provided New Data on Asthma (Maintenance and Reliever Therapy in Pediatric Asthma: A Concise Review of Recent Evidence-Part I). Respiratory Therapeutics Week. October 20, 2025; p 377.